71,219 Shares in Pfizer Inc. $PFE Bought by Applied Finance Capital Management LLC

Key Points

• Applied Finance Capital Management LLC has acquired 71,219 shares of Pfizer Inc. valued at approximately $1.726 million, highlighting ongoing institutional interest in the company.
• The quarterly earnings report indicated that Pfizer beat earnings expectations with $0.78 EPS and a revenue of $14.65 billion, marking a 10.3% increase compared to the previous year.
• Pfizer has declared a quarterly dividend of $0.43 per share, with a dividend yield of 7.1%, reflecting a payout ratio of 91.49%.

Applied Finance Capital Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 71,219 shares of the biopharmaceutical company's stock, valued at approximately $1,726,000.

Several other institutional investors have also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter worth about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer in the first quarter worth approximately $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer during the 2nd quarter valued at $29,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer in the 1st quarter valued at $35,000. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on PFE shares. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. UBS Group reiterated a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley reduced their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Finally, Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.13.

Pfizer Trading Down 0.7%

NYSE:PFE opened at $24.22 on Friday. The firm has a 50-day simple moving average of $24.89 and a 200-day simple moving average of $24.12. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.53. The firm has a market cap of $137.70 billion, a P/E ratio of 12.88, a P/E/G ratio of 0.81 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.